[Glycemic control and new prospects on insulinotherapy in diabetes mellitus type 1].
Except for contraindications, current treatment of DM1 is based on what we know as insulin intensive treatment. This modality includes the utilization of rapid insulins for controlling the postprandial hyperglycemic peaks, and insulins of intermediate or slow action with the objective of contributing some basal levels of insulin (bolus/basal type therapy). Although the intensive treatment does not avoid completely the appearance nor the progression of the microvascular complications, improvement of glycemic control reduces the risk of developing microvascular complications approximately between 35% and 75%, and its worsening diminishes the risk between 50% and 75%. New insulin analogues has possibly many and obvious advantages. New insulin analogues are a potentially effective alternative in the intensive treatment of the patients with DM1, and they represent the best way for implementing a <<bolus-basal>> type therapeutic regimen. Its balanced and individualized application can contribute for improvement metabolic control, including a reduction in the incidence of hypoglycemia.
Hernáez Rodríguez
R
R
Endrocrinología y Nutrición, ICMDiM, Hospital Clínic i Universitari de Barcelona, IDIBAPS, Barcelona, Spain.
Conget Donlo
I
I
D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D007328:Insulin